Apixaban Dosing Regimen for DVT Treatment

Initial Treatment Phase

• The American College of Cardiology recommends apixaban should be started at 10 mg orally twice daily for the first 7 days of therapy, which is a loading dose regimen that ensures rapid anticoagulation effect for acute management of DVT 1, 2
• Unlike some other DOACs (direct oral anticoagulants), apixaban does not require initial parenteral anticoagulation, according to the American College of Cardiology 1, 2

Maintenance Phase

• After the initial 7 days, the American College of Cardiology recommends transitioning to 5 mg orally twice daily, which should be continued for at least 3 months for provoked DVT 1
• For unprovoked DVT or patients with ongoing risk factors, the American College of Cardiology and the American College of Chest Physicians recommend considering longer treatment duration 1, 3

Extended Treatment Phase

• For patients requiring extended anticoagulation beyond 6 months, the American College of Cardiology recommends reducing the dose to 2.5 mg twice daily for secondary prevention, which helps minimize bleeding risk while maintaining efficacy for preventing recurrent DVT 2, 1

Advantages of Apixaban for DVT Treatment

• Apixaban has demonstrated similar efficacy to conventional treatment (LMWH/VKA) with reduced risk of major bleeding, according to the American College of Chest Physicians 3
• The fixed-dose regimen of apixaban eliminates the need for routine laboratory monitoring, as recommended by the American College of Cardiology 1

Cancer-Associated DVT

• In patients with DVT and cancer, recent evidence from the American College of Chest Physicians supports apixaban as a viable option, which has been shown to be noninferior to dalteparin for cancer-associated VTE 3